Campath Maintenance in Chronic Lymphocytic Leukemia

Stopped early · Not applicable

Conditions studied: Chronic Lymphocytic Leukemia

In brief

This is a study designed to test whether giving campath (also known as alemtuzumab) on a maintenance schedule will prolong the time until the patient requires chemotherapy.

Key facts

Study ID

NCT00587847

Run by

Northwell Health

People needed

12

Starts

2005-08-01

Expected to finish

2009-11-01

Last updated by the study team

2015-10-15

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Enrollment in this study is open to patients 18 years of age with confirmed chronic lymphocytic leukemia, a clinical response of stable disease or better to previous treatment, and an Eastern Cooperative Oncology Group performance status of 0-2

You may not qualify if…

• Treatment failure in more than 3 prior regimens
• Active secondary malignancy
• Central nervous system involvement with CLL
• History of significant allergic reaction to antibody therapies that required discontinuation of the antibody therapy
• History of HIV positivity
• Hepatitis C virus (HCV) positivity based upon core antigen testing
• Active infection, requiring treatment with antibiotic, antiviral, or antifungal agents
• Pregnancy or lactation
• Other severe, concurrent diseases or mental disorders

Where it is running

• Long Island Jewish Medical Center — New Hyde Park, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.